Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial.

Ostuzzi, Giovanni; Gastaldon, Chiara; Tettamanti, Mauro; Cartabia, Massimo; Monti, Igor; Aguglia, Andrea; Aguglia, Eugenio; Bartoli, Francesco; Callegari, Camilla; Canozzi, Andrea; Carbone, Elvira Anna; Carrà, Giuseppe; Caruso, Rosangela; Cavallotti, Simone; Chiappini, Stefania; Colasante, Fabrizio; Compri, Beatrice; D'Agostino, Armando; De Fazio, Pasquale; de Filippis, Renato; ... (2024). Tolerability of vortioxetine compared to selective serotonin reuptake inhibitors in older adults with major depressive disorder (VESPA): a randomised, assessor-blinded and statistician-blinded, multicentre, superiority trial. EClinicalMedicine, 69, p. 102491. Elsevier 10.1016/j.eclinm.2024.102491

Preview

Text 1-s2.0-S2589537024000701-main.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (802kB) | Preview

BACKGROUND

Major depressive disorder (MDD) is prevalent and disabling among older adults. Standing on its tolerability profile, vortioxetine might be a promising alternative to selective serotonin reuptake inhibitors (SSRIs) in such a vulnerable population.

METHODS

We conducted a randomised, assessor- and statistician-blinded, superiority trial including older adults with MDD. The study was conducted between 02/02/2019 and 02/22/2023 in 11 Italian Psychiatric Services. Participants were randomised to vortioxetine or one of the SSRIs, selected according to common practice. Treatment discontinuation due to adverse events after six months was the primary outcome, for which we aimed to detect a 12% difference in favour of vortioxetine. The study was registered in the online repository clinicaltrials.gov (NCT03779789).

FINDINGS

The intention-to-treat population included 179 individuals randomised to vortioxetine and 178 to SSRIs. Mean age was 73.7 years (standard deviation 6.1), and 264 participants (69%) were female. Of those on vortioxetine, 78 (44%) discontinued the treatment due to adverse events at six months, compared to 59 (33%) of those on SSRIs (odds ratio 1.56; 95% confidence interval 1.01-2.39). Adjusted and per-protocol analyses confirmed point estimates in favour of SSRIs, but without a significant difference. With the exception of the unadjusted survival analysis showing SSRIs to outperform vortioxetine, secondary outcomes provided results consistent with a lack of substantial safety and tolerability differences between the two arms. Overall, no significant differences emerged in terms of response rates, depressive symptoms and quality of life, while SSRIs outperformed vortioxetine in terms of cognitive performance.

INTERPRETATION

As opposed to what was previously hypothesised, vortioxetine did not show a better tolerability profile compared to SSRIs in older adults with MDD in this study. Additionally, hypothetical advantages of vortioxetine on depression-related cognitive symptoms might be questioned. The study's statistical power and highly pragmatic design allow for generalisability to real-world practice.

FUNDING

The study was funded by the Italian Medicines Agency within the "2016 Call for Independent Drug Research".

Interest & Impact

Downloads

2 since deposited on 22 Feb 2024
2 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item